Navigation Links
Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
Date:3/11/2009

INTERIM DATA FROM PHASE 3 CLINICAL TRIAL FOR NATURLOSE(R) ANTICIPATED BY FALL

BETHESDA, Md., March 11 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the postponement of its 2009 Annual Shareholders Meeting. Previously scheduled for May, the meeting will instead be held during the Fall of 2009, when it is anticipated that interim data from its pivotal Phase 3 clinical trial of Naturlose as a drug for Type 2 diabetes will be available.

The Company's Board of Directors, based on the recommendation of its senior management team, has decided to hold the meeting in early Fall so that an interim analysis of the data from the Company's Phase 3 trial can be shared with Spherix's shareholders. The date for the meeting will be set based on the Company's early analysis of the trial data. The trial is currently on schedule, and Spherix expects to have enough patients by the end of the second quarter to perform the interim analysis, with the results expected to be ready to be presented at a meeting later this year.

Dr. Claire Kruger, Chief Executive Officer of Spherix, said, "Postponing this year's Annual Shareholders Meeting until we are able to share the results of the interim analysis with our shareholders is a logical decision for us. We believe this will be a significant moment for both Spherix and its shareholders, and we are enthusiastic about the trial's potential to demonstrate the efficacy of Naturlose as a treatment for Type 2 diabetes."

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverage
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
8. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... May 11, 2011 Reportlinker.com announces ... is available in its catalogue: ... 2011 – Generics Market Overview: Patent ... uptake despite tougher market conditions ...
... Daiichi Sankyo announced that applications have been submitted ... of metastatic melanoma to the U.S. Food and Drug ... a pre-marketing application for approval for a companion diagnostic ... also will be registered in Europe.  Vemurafenib is an ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 5Vemurafenib New Drug Application Submitted to FDA for Melanoma 2Vemurafenib New Drug Application Submitted to FDA for Melanoma 3Vemurafenib New Drug Application Submitted to FDA for Melanoma 4
(Date:6/19/2013)... June 19, 2013 Recently, SoCal CEO Magazine ... County held their third in a series of six workshops ... of Respect and helped place the mosaic tiles in their permanent ... her parents, Cathy and Greg Maxwell. , This mural project ... idea that took root over three years ago with the goal ...
(Date:6/19/2013)... June 19, 2013 The US Food and ... third ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , ... in February 2013. The FDA announced the approval of the ... for primary augmentations in women 22 years old ... age. , The FDA’s approval comes after six years ...
(Date:6/19/2013)... victims has been "time equals brain." That,s because getting a ... that dissolves the stroke-causing blood clot can make a significant ... , But specific information has been limited on ... known as a tissue plasminogen activator, or tPA influences ... type of stroke. , Now, a team led ...
(Date:6/19/2013)... fact that the incidence of cancer is many fold ... still have an inadequate understanding on how best to ... patients are occasionally included in clinical trials, those elderly ... elderly patients. Thus, the broader elderly patient population is ... in the Elderly Task Force is now starting a ...
(Date:6/19/2013)... 2013 Fit Body Boot Camp in ... a charity boot camp in order to support Orlando resident, ... boot camp franchise hosted the Brent Can Breathe fundraiser ... 75 boot camp participants and collected over $700. , Officially ... the second fundraiser held for Orlando local Brent Snyder, 24, ...
Breaking Medicine News(10 mins):Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2
... guidelines for school sports, survey shows , WEDNESDAY, June ... on concussions in school sports, the majority are unaware ... most report widespread pressure to return young athletes to ... came from the C.S. Mott Children,s Hospital National Poll ...
... ... senior living communities. A senior care blog and Q&A area also offer helpful advice ... ... 2010 -- AssistedLivingFacilities.org is a new website that has launched to help senior citizens ...
... Dr. DeSilva hosts ... , ... 2010-- Want a chance to ask the health experts? Swanson Health Talk Radio, hosted by ... and authors questions covering the topics of vitamins and supplements, homeopathic medicine, exercise and fitness, ...
... ... and fitness fun for the whole family. Free to download with $.99 in-app purchase to ... streetball players and ball handlers. , ... Los Angeles, CA (PRWEB) June 16, 2010 -- Luis Da Silva Jr. aka TRIKZ ...
... ... above its laser lipolysis competitors by empowering its patients with education about liposuction and body ... ... standard of Soluna MD is its commitment to patient education. The Soluna MD staff, led ...
... ... aiding in the creation of healthy serotonin levels , ... Springville, UT (PRWEB) June 16, 2010 -- Nutrifect introduces Serofil, a ... restful sleep ; reduces cravings for junk food; and assists with healthy fat loss ...
Cached Medicine News:Health News:Parents Ill-Informed About Kids' Concussion Risks 2Health News:Seniors Have a New Resource to Research Assisted Living Housing Options 2Health News:Seniors Have a New Resource to Research Assisted Living Housing Options 3Health News:Dr. DeSilva Hosts Swanson Health Talk Radio on HealthRadio.net 2Health News:Dr. DeSilva Hosts Swanson Health Talk Radio on HealthRadio.net 3Health News:Trikz Streetball Basketball iTunes App Promotion: Only $.99 to Unlock All Content for the iPhone, iPod Touch, and iPad 2Health News:Trikz Streetball Basketball iTunes App Promotion: Only $.99 to Unlock All Content for the iPhone, iPod Touch, and iPad 3Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 2Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 3Health News:Healthy Serotonin Levels Shown to Positively Affect many Important Functions of the Mind and Body. 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: